Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel

 
• By Sue Sutter
FDA Advisory Committee Feature image
AdComm endorsed Cyramza labeling expansion by slimmest of margins but overwhelmingly recommended against Tookad's approval.

More from US FDA Performance Tracker

More from Regulatory Trackers